NRx Pharmaceuticals reports Q1 net loss of $5.5M, advances NDA filings and HOPE clinic acquisitions

NRX Pharmaceuticals, Inc.

Net loss narrowed to $5.5M for Q1 2025 from $6.5M in Q1 2024; operating loss $3.8M vs $6.0M.
Cash & cash equivalents $5.5M at March 31, 2025; company expects sufficient runway through end of 2025.
NDA for NRX-100 (IV ketamine) filing on track for Q2 2025; FDA waived $4.3M filing fee; U.S. patent application filed.
HOPE Therapeutics signed $7.8M debt term sheet with Universal Capital and $2.5M strategic investment for clinic acquisitions; initial clinics have ~$15M pro-forma revenue.
NRX-101 NDA submission for suicidal bipolar depression on track for 2025; anticipates PDUFA before year-end.

item 2.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.